NEW YORK , March 22, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Obagi Medical Products, Inc. ("Obagi" or the "Company") (NasdaqGS: OMPI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Valeant Pharmaceuticals International, Inc. (NYSE: VRX) .
Sign-up for SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Obagi Medical Products, Inc. in Connection with the Sale of the Company to Valeant Pharmaceuticals International, Inc. investment picks